139 results on '"Svane, Maria"'
Search Results
102. Svane, Maria Saur
- Author
-
Svane, Maria Saur and Svane, Maria Saur
- Published
- 2014
103. Simultaneous measurements of gaseous emissions, particulates and noise from individual vehicles in traffic
- Author
-
Jerksjö, Martin, Fridell, Erik, Gustafson, Andreas, Larsson, Krister, Jonasson, Hans, Svane, Maria, Hak, Claudia, and Hallquist, Mattias
- Subjects
particles ,noise ,emissions ,Traffic ,vehicles - Abstract
In order to identify vehicles and traffic situations that have a negative impact on the environment, it is important to be able to measure emissions from individual vehicles in traffic. In this study an attempt is made to measure gases, particles and noise emitted from single vehicles in normal traffic. An apparatus for Fuel Efficiency Automobile Test (FEAT), by which emissions of NO, CO, HC and CO2 are measured, was combined with particle instruments for both total and size-distribution measurements, as well as noise measurements. The sampling of particles was done utilising a tube system for sampling on the road together with a dilution system. The noise measurements were done with two microphones at different heights. The measurements show that it is feasible to study regulated emissions, particle emissions and noise emissions from individual vehicles in normal traffic. Noise data was collected from ca 200 individual vehicles during the measurement campaign and the emissions of some of the vehicles were evaluated. The measurements were manually supervised and the evaluations mainly made by hand. The experiences of this project are encouraging and show that it is possible to perform measurements of noise emissions from individual vehicles automatically. One way to achieve this would be by extending the FEAT system so that it also measures noise emission. Further it is important to perform sampling and evaluation automatically and to use computerized procedures for the evaluation. By using CO2 data together with the particle data, we were able to obtain PM emission factors for individual vehicles. We also showed that the particle size-distribution can be obtained from individual vehicles in traffic when using a fast instrument. This also, in principle, allows for the separation of particles emitted from the engine and particles from road and tyre wear. The results show that the emissions of particles vary significantly from vehicle to vehicle. A variation range of two orders of magnitude (between 8.5 x 1011 and 1.2 x 1014 part km 1 veh 1) has been observed. The FEAT systems together with a system for speed and acceleration monitoring, were able to record how the emissions of NO, HC, CO and CO2 depend on speed and acceleration. A general conclusion is that after some further improvement the setup should suitable for more systematic mapping of vehicle tailpipe and noise emissions. Further, the system may be used for identifying individual vehicles that can be considered large emitters In order to identify vehicles and traffic situations that have a negative impact on the environment, it is important to be able to measure emissions from individual vehicles in traffic. In this study an attempt is made to measure gases, particles and noise emitted from single vehicles in normal traffic. An apparatus for Fuel Efficiency Automobile Test (FEAT), by which emissions of NO, CO, HC and CO2 are measured, was combined with particle instruments for both total and size-distribution measurements, as well as noise measurements. The sampling of particles was done utilising a tube system for sampling on the road together with a dilution system. The noise measurements were done with two microphones at different heights. The measurements show that it is feasible to study regulated emissions, particle emissions and noise emissions from individual vehicles in normal traffic. Noise data was collected from ca 200 individual vehicles during the measurement campaign and the emissions of some of the vehicles were evaluated. The measurements were manually supervised and the evaluations mainly made by hand. The experiences of this project are encouraging and show that it is possible to perform measurements of noise emissions from individual vehicles automatically. One way to achieve this would be by extending the FEAT system so that it also measures noise emission. Further it is important to perform sampling and evaluation automatically and to use computerized procedures for the evaluation. By using CO2 data together with the particle data, we were able to obtain PM emission factors for individual vehicles. We also showed that the particle size-distribution can be obtained from individual vehicles in traffic when using a fast instrument. This also, in principle, allows for the separation of particles emitted from the engine and particles from road and tyre wear. The results show that the emissions of particles vary significantly from vehicle to vehicle. A variation range of two orders of magnitude (between 8.5 x 1011 and 1.2 x 1014 part km 1 veh 1) has been observed. The FEAT systems together with a system for speed and acceleration monitoring, were able to record how the emissions of NO, HC, CO and CO2 depend on speed and acceleration. A general conclusion is that after some further improvement the setup should suitable for more systematic mapping of vehicle tailpipe and noise emissions. Further, the system may be used for identifying individual vehicles that can be considered large emitters
- Published
- 2007
104. Aerosol chemistry on the single particle level - an experimental study
- Author
-
Svane, Maria 1957
- Subjects
alkali ,ambient air ,surface ionization ,Aerosol mass spectrometry ,biomass combustion - Published
- 2005
105. Bariatric Surgery - Effects on Obesity and Related co-Morbidities
- Author
-
Svane, Maria, primary and Madsbad, Sten, additional
- Published
- 2014
- Full Text
- View/download PDF
106. On-Line Chemical Analysis of Individual Alkali-Containing Aerosol Particles by Surface Ionization Combined with Time-of-Flight Mass Spectrometry
- Author
-
Svane, Maria, Gustafsson, Torbjorn L., Kovacevik, Borka, Noda, Jun, Andersson, Patrik U., Nilsson, E. Douglas, Pettersson, Jan B. C., Svane, Maria, Gustafsson, Torbjorn L., Kovacevik, Borka, Noda, Jun, Andersson, Patrik U., Nilsson, E. Douglas, and Pettersson, Jan B. C.
- Abstract
An aerosol mass spectrometer for measurements of the alkali metal content in individual submicron aerosol particles is presented. The instrument combines surface ionization of individual particles on a hot platinum surface with orthogonal acceleration time-of-flight mass spectrometry. The instrument simultaneously provides the content of different alkali metal elements in single particles with high sensitivity. The instrument is characterized in laboratory experiments, and determination of the alkali metal content is demonstrated for particle diameters of 50-500 nm. The technique is demonstrated in ambient air measurements at an urban background site, and sea spray particles and particles originating from biomass burning are identified based on their content of sodium and potassium. Possible further improvements and applications of the technique are discussed., authorCount :7
- Published
- 2009
- Full Text
- View/download PDF
107. In vivo and in vitro degradation of peptide YY3-36 to inactive peptide YY3-34 in humans.
- Author
-
Toräng, Signe, Bojsen-Møller, Kirstine Nyvold, Svane, Maria Saur, Hartmann, Bolette, Rosenkilde, Mette Marie, Madsbad, Sten, and Holst, Jens Juul
- Subjects
C-terminal residues ,PEPTIDE YY ,GASTROINTESTINAL hormones ,PEPTIDES ,PROTEINS - Abstract
The article discusses a study on whether COOH-terminal degradation of peptide YY (PYY) with a formation of PYY
3-34 also occurs in humans. It suggests that PYY levels determined by existing assays do not reflect concentrations of biologically active peptides and assumptions about the physiological functions of PYY at these levels were inaccurate.- Published
- 2016
- Full Text
- View/download PDF
108. Perineal hernia after laparoscopic abdominoperineal resection—reconstruction of the pelvic floor with a biological mesh (Permacol™)
- Author
-
Svane, Maria, primary and Bulut, Orhan, additional
- Published
- 2011
- Full Text
- View/download PDF
109. On-Line Chemical Analysis of Individual Alkali-Containing Aerosol Particles by Surface Ionization Combined with Time-of-Flight Mass Spectrometry
- Author
-
Svane, Maria, primary, Gustafsson, Torbjörn L., additional, Kovacevik, Borka, additional, Noda, Jun, additional, Andersson, Patrik U., additional, Nilsson, E. Douglas, additional, and Pettersson, Jan B.C., additional
- Published
- 2009
- Full Text
- View/download PDF
110. A new approach to in-situ determination of roadside particle emission factors of individual vehicles under conventional driving conditions
- Author
-
Hak, Claudia S., primary, Hallquist, Mattias, additional, Ljungström, Evert, additional, Svane, Maria, additional, and Pettersson, Jan B.C., additional
- Published
- 2009
- Full Text
- View/download PDF
111. Potassium, Chlorine, and Sulfur in Ash, Particles, Deposits, and Corrosion during Wood Combustion in a Circulating Fluidized-Bed Boiler
- Author
-
Davidsson, Kent O., primary, Åmand, Lars-Erik, additional, Leckner, Bo, additional, Kovacevik, Borka, additional, Svane, Maria, additional, Hagström, Magnus, additional, Pettersson, Jan B. C., additional, Pettersson, Jesper, additional, Asteman, Henrik, additional, Svensson, Jan-Erik, additional, and Johansson, Lars-Gunnar, additional
- Published
- 2006
- Full Text
- View/download PDF
112. Cesium as a Tracer for Alkali Processes in a Circulating Fluidized Bed Reactor
- Author
-
Svane, Maria, primary, Hagström, Magnus, additional, Davidsson, Kent O., additional, Boman, J., additional, and Pettersson, Jan B. C., additional
- Published
- 2006
- Full Text
- View/download PDF
113. On-line alkali analysis of individual aerosol particles in urban air
- Author
-
Svane, Maria, primary, Janhäll, Sara, additional, Hagström, Magnus, additional, Hallquist, Mattias, additional, and Pettersson, J.B.C., additional
- Published
- 2005
- Full Text
- View/download PDF
114. Online Measurements of Individual Alkali-Containing Particles Formed in Biomass and Coal Combustion: Demonstration of an Instrument Based on Surface Ionization Technique
- Author
-
Svane, Maria, primary, Hagström, Magnus, additional, and Pettersson, Jan B. C., additional
- Published
- 2004
- Full Text
- View/download PDF
115. Chemical Analysis of Individual Alkali-Containing Aerosol Particles: Design and Performance of a Surface Ionization Particle Beam Mass Spectrometer
- Author
-
Svane, Maria, primary, Hagstr�m, Magnus, additional, and Pettersson, Jan, additional
- Published
- 2004
- Full Text
- View/download PDF
116. Bariatric Surgery - Effects on Obesity and Related co-Morbidities
- Author
-
Saur Svane, Maria and Madsbad, Sten
- Abstract
Laparoscopic adjustable gastric banding (LAGB), laparoscopic Roux-en-Y gastric bypass (RYGB) and laparoscopic sleeve gastrectomy (SG) are the three most commonly performed bariatric procedures. Obesity responds well to bariatric surgery, with major long-lasting weight loss that is most pronounced after RYGB and SG, where the mean weight loss is about 40 kg or 15 body mass index (BMI) units. Some of the benefits after RYGB and SG are independent of weight loss, and the remission of type 2 diabetes is observed a few days after the operation; this depends on changes in insulin sensitivity and gut hormone responses, especially a 10-fold increase in glucagon-like peptide-1 (GLP-1), which improves insulin secretion. After gastric banding, the remission of diabetes depends more on weight loss. Bariatric surgery reduces cardiovascular risk factors including hypertension, lipid disturbances, non-alcoholic fatty liver, musculoskeletal pain and reduces mortality of diabetes, cardiovascular diseases and cancers. Bariatric surgery also improves quality of life. The acute complications of surgery are infection, bleeding and anastomotic leak. Long-term complications are nutritional deficiencies, including vitamins and minerals, and anemia. Some patients have dumping after meals, and a few patients will develop postprandial hypoglycemia after RYGB. About 25% of patients require plastic surgery to provide relief from excessive skin tissue.
- Published
- 2014
117. Potassium, Chlorine, and Sulfur in Ash, Particles, Deposits, and Corrosion during Wood Combustion in a Circulating Fluidized-Bed Boiler.
- Author
-
Davidsson, Kent O., Åmand, Lars-Erik, Leckner, Bo, Kovacevik, Borka, Svane, Maria, Hagström, Magnus, Pettersson, Jan B. C., Pettersson, Jesper, Asteman, Henrik, Svensson, Jan-Erik, and Johansson, Lars-Gunnar
- Published
- 2007
- Full Text
- View/download PDF
118. Online Measurements of Individual Alkali-Containing Particles Formed in Biomass and Coal Combustion: Demonstration of an Instrument Based on Surface Ionization Technique.
- Author
-
Svane, Maria, Hagström, Magnus, and Pettersson, Jan B. C.
- Published
- 2005
- Full Text
- View/download PDF
119. New Lessons from the gut: Studies of the role of gut peptides in weight loss and diabetes resolution after gastric bypass and sleeve gastrectomy.
- Author
-
Holst, Jens Juul, Madsbad, Sten, Bojsen-Møller, Kirstine Nyvold, Dirksen, Carsten, and Svane, Maria
- Subjects
- *
SLEEVE gastrectomy , *GASTRIC bypass , *WEIGHT loss , *INSULIN , *GHRELIN , *BARIATRIC surgery , *GASTRIC banding , *GASTROINTESTINAL hormones - Abstract
It has been known since 2005 that the secretion of several gut hormones changes radically after gastric bypass operations and, although more moderately, after sleeve gastrectomy but not after gastric banding. It has therefore been speculated that increased secretion of particularly GLP-1 and Peptide YY (PYY), which both inhibit appetite and food intake, may be involved in the weight loss effects of surgery and for improvements in glucose tolerance. Experiments involving inhibition of hormone secretion with somatostatin, blockade of their actions with antagonists, or blockade of hormone formation/activation support this notion. However, differences between results of bypass and sleeve operations indicate that distinct mechanisms may also be involved. Although the reductions in ghrelin secretion after sleeve gastrectomy would seem to provide an obvious explanation, experiments with restoration of ghrelin levels pointed towards effects on insulin secretion and glucose tolerance rather than on food intake. It seems clear that changes in GLP-1 secretion are important for insulin secretion after bypass and appear to be responsible for postbariatric hypoglycemia in glucose-tolerant individuals; however, with time the improvements in insulin sensitivity, which in turn are secondary to the weight loss, may be more important. Changes in bile acid metabolism do not seem to be of particular importance in humans. • Bypass and SG cause elevated levels of appetite regulating gut hormones. • When patients are matched for weight loss there are major hormone differences. • PYY and GLP-1 are more important for bypass, ghrelin and GIP more important for SG. • Weight loss improvement of insulin resistance is important for glucose tolerance. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
120. Effect of ghrelin on glucose tolerance, gut hormones, appetite, and food intake after sleeve gastrectomy.
- Author
-
Hedbäck N, Dichman ML, Hindsø M, Dirksen C, Jørgensen NB, Bojsen-Møller KN, Kristiansen VB, Rehfeld JF, Hartmann B, Holst JJ, Svane MS, and Madsbad S
- Subjects
- Humans, Male, Adult, Female, Middle Aged, Insulin blood, Obesity, Morbid surgery, Obesity, Morbid metabolism, Gastrointestinal Hormones metabolism, Gastrointestinal Hormones blood, Glucose Tolerance Test, Insulin Resistance physiology, Double-Blind Method, Obesity surgery, Obesity metabolism, Ghrelin blood, Ghrelin analogs & derivatives, Gastrectomy, Appetite drug effects, Eating drug effects, Blood Glucose metabolism, Blood Glucose drug effects, Postprandial Period drug effects
- Abstract
Ghrelin is an appetite-stimulating hormone secreted from the gastric mucosa in the fasting state, and secretion decreases in response to food intake. After sleeve gastrectomy (SG), plasma concentrations of ghrelin decrease markedly. Whether this affects appetite and glucose tolerance postoperatively is unknown. We investigated the effects of ghrelin infusion on appetite and glucose tolerance in individuals with obesity before and 3 mo after SG. Twelve participants scheduled for SG were included. Before and 3 mo after surgery, a mixed-meal test followed by an ad libitum meal test was performed with concomitant infusions of acyl-ghrelin (1 pmol/kg/min) or placebo. Infusions began 60 min before meal intake to reach a steady state before the mixed-meal and were continued throughout the study day. Two additional experimental days with 0.25 pmol/kg/min and 10 pmol/kg/min of acyl-ghrelin infusions were conducted 3 mo after surgery. Both before and after SG, postprandial glucose concentrations increased dose dependently during ghrelin infusions compared with placebo. Ghrelin infusions inhibited basal and postprandial insulin secretion rates, resulting in lowered measures of β-cell function, but no effect on insulin sensitivity was seen. Ad libitum meal intake was unaffected by the administration of ghrelin. In conclusion, ghrelin infusion increases postprandial plasma glucose concentrations and impairs β-cell function before and after SG but has no effect on ad libitum meal intake. We speculate that the lower concentration of ghrelin after SG may impact glucose metabolism following this procedure. NEW & NOTEWORTHY Ghrelin's effect on glucose tolerance and food intake following sleeve gastrectomy (SG) was evaluated. Acyl-ghrelin was infused during a mixed-meal and ad libitum meals before and 3 mo after surgery. Postprandial glucose concentrations increased during ghrelin infusions, both before and after surgery, while insulin production was inhibited. However, ad libitum meal intake did not differ during ghrelin administration compared with placebo. The decreased ghrelin concentration following SG may contribute to the glycemic control after surgery.
- Published
- 2024
- Full Text
- View/download PDF
121. Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): A randomized, double-blind, placebo-controlled trial.
- Author
-
Dejgaard TF, Frandsen CS, Kielgast U, Størling J, Overgaard AJ, Svane MS, Olsen MH, Thorsteinsson B, Andersen HU, Krarup T, Holst JJ, and Madsbad S
- Subjects
- Humans, Male, Female, Double-Blind Method, Adult, Middle Aged, Insulin-Secreting Cells drug effects, Insulin-Secreting Cells metabolism, Blood Glucose drug effects, Blood Glucose metabolism, Remission Induction, Treatment Outcome, Glycated Hemoglobin metabolism, Glycated Hemoglobin drug effects, Glycated Hemoglobin analysis, Area Under Curve, Liraglutide therapeutic use, Liraglutide pharmacology, Diabetes Mellitus, Type 1 drug therapy, Diabetes Mellitus, Type 1 blood, Hypoglycemic Agents therapeutic use, Insulin therapeutic use, C-Peptide blood, Insulin Secretion drug effects
- Abstract
Aim: To test the effect of the glucagon-like peptide-1 receptor agonist, liraglutide, on residual beta-cell function in adults with newly diagnosed type 1 diabetes., Materials and Methods: In a multicentre, double-blind, parallel-group trial, adults with newly diagnosed type 1 diabetes and stimulated C-peptide of more than 0.2 nmol/L were randomized (1:1) to 1.8-mg liraglutide (Victoza) or placebo once daily for 52 weeks with 6 weeks of follow-up with only insulin treatment. The primary endpoint was the between-group difference in C-peptide area under the curve (AUC) following a liquid mixed-meal test after 52 weeks of treatment., Results: Sixty-eight individuals were randomized. After 52 weeks, the 4-hour AUC C-peptide response was maintained with liraglutide, but decreased with placebo (P = .002). Six weeks after end-of-treatment, C-peptide AUCs were similar for liraglutide and placebo. The average required total daily insulin dose decreased from 0.30 to 0.23 units/kg/day with liraglutide, but increased from 0.29 to 0.43 units/kg/day in the placebo group at week 52 (P < .001). Time without the need for insulin treatment was observed in 13 versus two patients and lasted for 22 weeks (from 3 to 52 weeks) versus 6 weeks (from 4 to 8 weeks) on average for liraglutide and placebo, respectively. Patients treated with liraglutide had fewer episodes of hypoglycaemia compared with placebo-treated patients. The adverse events with liraglutide were predominantly gastrointestinal and transient., Conclusions: Treatment with liraglutide improves residual beta-cell function and reduces the dose of insulin during the first year after diagnosis. Beta-cell function was similar at 6 weeks postliraglutide treatment., (© 2024 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
122. Effects of Exogenous GIP and GLP-2 on Bone Turnover in Individuals With Type 2 Diabetes.
- Author
-
Skov-Jeppesen K, Christiansen CB, Hansen LS, Windeløv JA, Hedbäck N, Gasbjerg LS, Hindsø M, Svane MS, Madsbad S, Holst JJ, Rosenkilde MM, and Hartmann B
- Subjects
- Humans, Male, Middle Aged, Aged, Adult, Bone Density drug effects, Gastric Inhibitory Polypeptide blood, Glucagon-Like Peptide 2 blood, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 metabolism, Diabetes Mellitus, Type 2 blood, Bone Remodeling drug effects, Cross-Over Studies
- Abstract
Context: Individuals with type 2 diabetes (T2D) have an increased risk of bone fractures despite normal or increased bone mineral density. The underlying causes are not well understood but may include disturbances in the gut-bone axis, in which both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-2 (GLP-2) are regulators of bone turnover. Thus, in healthy fasting participants, both exogenous GIP and GLP-2 acutely reduce bone resorption., Objective: The objective of this study was to investigate the acute effects of subcutaneously administered GIP and GLP-2 on bone turnover in individuals with T2D., Methods: We included 10 men with T2D. Participants met fasting in the morning on 3 separate test days and were injected subcutaneously with GIP, GLP-2, or placebo in a randomized crossover design. Blood samples were drawn at baseline and regularly after injections. Bone turnover was estimated by circulating levels of collagen type 1 C-terminal telopeptide (CTX), procollagen type 1 N-terminal propeptide (P1NP), sclerostin, and PTH., Results: GIP and GLP-2 significantly reduced CTX to (mean ± SEM) 66 ± 7.8% and 74 ± 5.9% of baseline, respectively, compared with after placebo (P = .001). In addition, P1NP and sclerostin increased acutely after GIP whereas a decrease in P1NP was seen after GLP-2. PTH levels decreased to 67 ± 2.5% of baseline after GLP-2 and to only 86 ± 3.4% after GIP., Conclusion: Subcutaneous GIP and GLP-2 affect CTX and P1NP in individuals with T2D to the same extent as previously demonstrated in healthy individuals., (© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society.)
- Published
- 2024
- Full Text
- View/download PDF
123. The impact of surgery and oncological treatment on risk of type 2 diabetes onset in patients with colorectal cancer: nationwide cohort study in Denmark.
- Author
-
Krag C, Svane MS, Madsbad S, Graversen SB, Christensen JF, Sørensen TIA, Lehrskov LL, and Laurberg T
- Subjects
- Humans, Denmark epidemiology, Male, Female, Aged, Middle Aged, Cohort Studies, Risk Factors, Incidence, Aged, 80 and over, Adult, Registries, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 epidemiology, Colorectal Neoplasms epidemiology, Colorectal Neoplasms surgery
- Abstract
Background: Comorbidity with type 2 diabetes (T2D) results in worsening of cancer-specific and overall prognosis in colorectal cancer (CRC) patients. The treatment of CRC per se may be diabetogenic. We assessed the impact of different types of surgical cancer resections and oncological treatment on risk of T2D development in CRC patients., Methods: We developed a population-based cohort study including all Danish CRC patients, who had undergone CRC surgery between 2001 and 2018. Using nationwide register data, we identified and followed patients from date of surgery and until new onset of T2D, death, or end of follow-up., Results: In total, 46,373 CRC patients were included and divided into six groups according to type of surgical resection: 10,566 Right-No-Chemo (23%), 4645 Right-Chemo (10%), 10,151 Left-No-Chemo (22%), 5257 Left-Chemo (11%), 9618 Rectal-No-Chemo (21%), and 6136 Rectal-Chemo (13%). During 245,466 person-years of follow-up, 2556 patients developed T2D. The incidence rate (IR) of T2D was highest in the Left-Chemo group 11.3 (95% CI: 10.4-12.2) per 1000 person-years and lowest in the Rectal-No-Chemo group 9.6 (95% CI: 8.8-10.4). Between-group unadjusted hazard ratio (HR) of developing T2D was similar and non-significant. In the adjusted analysis, Rectal-No-Chemo was associated with lower T2D risk (HR 0.86 [95% CI 0.75-0.98]) compared to Right-No-Chemo.For all six groups, an increased level of body mass index (BMI) resulted in a nearly twofold increased risk of developing T2D., Conclusions: This study suggests that postoperative T2D screening should be prioritised in CRC survivors with overweight/obesity regardless of type of CRC treatment applied., Funding: The Novo Nordisk Foundation ( NNF17SA0031406) ; TrygFonden (101390; 20045; 125132)., Competing Interests: CK, MS, SM, SG, JC, TS, LL, TL No competing interests declared, (© 2023, Krag, Svane et al.)
- Published
- 2024
- Full Text
- View/download PDF
124. Change in abdominal obesity after colon cancer surgery - effects of left-sided and right-sided colonic resection.
- Author
-
Kays Mohammed Ali Y, Dolin TG, Damm Nybing J, Lykke J, Hvid Linden F, Høgh-Schmidt E, Sørensen TIA, Christensen JF, Nielsen YJW, Stenfatt Larsen J, Madsbad S, Sidenius Johansen J, Svane MS, and Lang Lehrskov L
- Subjects
- Male, Humans, Female, Obesity complications, Obesity surgery, Obesity epidemiology, Subcutaneous Fat, Tomography, X-Ray Computed, Intra-Abdominal Fat diagnostic imaging, Intra-Abdominal Fat metabolism, Obesity, Abdominal complications, Obesity, Abdominal diagnostic imaging, Obesity, Abdominal surgery, Colonic Neoplasms surgery
- Abstract
Background: Excess abdominal visceral adipose tissue (VAT) is associated with metabolic diseases and poor survival in colon cancer (CC). We assessed the impact of different types of CC surgery on changes in abdominal fat depots., Material and Methods: Computed tomography (CT)-scans performed preoperative and 3 years after CC surgery were analyzed at L3-level for VAT, subcutaneous adipose tissue (SAT) and total adipose tissue (TAT) areas. We assessed changes in VAT, SAT, TAT and VAT/SAT ratio after 3 years and compared the changes between patients who had undergone left-sided and right-sided colonic resection in the total population and in men and women separately., Results: A total of 134 patients with stage I-III CC undergoing cancer surgery were included. Patients who had undergone left-sided colonic resection had after 3 years follow-up a 5% (95% CI: 2-9%, p < 0.01) increase in abdominal VAT, a 4% (95% CI: 2-6%, p < 0.001) increase in SAT and a 5% increase (95% CI: 2-7%, p < 0.01) in TAT. Patients who had undergone right-sided colonic resection had no change in VAT, but a 6% (95% CI: 4-9%, p < 0.001) increase in SAT and a 4% (95% CI: 1-7%, p < 0.01) increase in TAT after 3 years. Stratified by sex, only males undergoing left-sided colonic resection had a significant VAT increase of 6% (95% CI: 2-10%, p < 0.01) after 3 years., Conclusion: After 3 years follow-up survivors of CC accumulated abdominal adipose tissue. Notably, those who underwent left-sided colonic resection had increased VAT and SAT, whereas those who underwent right-sided colonic resection demonstrated solely increased SAT., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
125. Kinetics of insulin and C-peptide and estimation of prehepatic insulin secretion rates after intravenous glucose stimulation using arterial versus venous blood sampling in healthy males.
- Author
-
Wriedt EB, Kielgast U, Svane MS, Møller S, and Madsbad S
- Subjects
- Male, Humans, Insulin Secretion, C-Peptide, Glucose Tolerance Test, Arteries metabolism, Blood Glucose, Kinetics, Insulin, Glucose pharmacology
- Abstract
An intravenous glucose-infusion of 0.3 g glucose per Kg body weight was administered over 1 min in nine healthy males with simultaneous blood sampling from the hepatic vein, femoral artery and a peripheral vein. Insulin secretion rates (ISR) were determined by the Eaton method and the ISEC method using C-peptide concentrations from arterial and peripheral venous blood. First phase (0-10 min), second phase (10-60 min), and total insulin secretion (0-60 min) were calculated as the incremental areas (iAUC) above baseline. The primary endpoint was first phase insulin response. The first phase insulin response in artery and venous blood did not differ with the Eaton method ( p = 0.25), but was significantly greater with the ISEC method in arterial compared with venous blood ( p < 0.05). The first phase insulin responses did not differ between methods in artery ( p = 0.73) or venous blood ( p = 0.73). The first phase responses of insulin and C-peptide were significant higher in the hepatic vein compared with those in the artery ( p < 0.05) and peripheral vein ( p < 0.05) but did not differ significantly between the artery compared with the peripheral vein for insulin ( p = 0.09) or C-peptide ( p = 0.26). Prehepatic insulin secretion rates did not differ between the Eaton and ISEC methods, but with the ISEC method the first phase insulin response was significantly greater in arterial compared with venous blood. The first phase insulin response differs when calculated from plasma insulin or C-peptide and depends on sample sites.
- Published
- 2024
- Full Text
- View/download PDF
126. Primary weight loss failure after Roux-en-Y gastric bypass is characterized by impaired gut-hormone mediated regulation of food intake.
- Author
-
Bojsen-Møller KN, Svane MS, Martinussen C, Dirksen C, Jørgensen NB, Jensen JB, Jensen CZ, Torekov SS, Kristiansen VB, Rehfeld JF, Bork-Jensen J, Grarup N, Hansen T, Hartmann B, Holst JJ, and Madsbad S
- Subjects
- Humans, Female, Ghrelin, Octreotide pharmacology, Peptide YY, Glucagon-Like Peptide 1, Cholecystokinin, Eating, Weight Loss physiology, Gastric Bypass, Gastrointestinal Hormones
- Abstract
Background/objectives: After Roux-en-Y gastric bypass (RYGB) a subset of patients never obtain excess BMI loss (EBMIL) > 50% and are categorized as having primary weight loss (WL) failure. We hypothesized that postprandial concentrations of glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) would be lower in patients with primary WL failure compared with patients with successfully maintained WL. Furthermore, that inhibition of gut hormone secretions would increase ad libitum food intake less in patients with primary WL failure., Subjects/methods: Twenty women with primary WL failure (LowEBMIL < 50%) were individually matched to twenty women with successful WL (HighEBMIL > 60%) on age, preoperative BMI and time from RYGB. On separate days performed in a random order, patient-blinded subcutaneous injections of octreotide or saline (placebo) were followed by a fixed breakfast and an ad libitum lunch with blood sampling for appetite regulating hormones and Visual-Analogue-Scale (VAS)-scoring of hunger/satiety. Furthermore, participants underwent gene variant analysis for GLP-1, PYY and their receptors, indirect calorimetry, dual-energy X-ray absorptiometry (DXA)-scans, 4-days at-home food registration and 14-days step counting., Results: On placebo days, postprandial GLP-1, PYY and cholecystokinin (CCK) concentrations were similar between groups after breakfast. Fasting ghrelin was lower in LowEBMIL, but the postprandial suppression was similar. LowEBMIL had lower satiety VAS-scores and less suppression of hunger VAS-scores. Gene variants did not differ between groups. Octreotide diminished GLP-1, PYY, CCK and ghrelin concentrations in both groups. Octreotide did not affect ad libitum food intake in LowEBMIL (-1% [-13, 12], mean [95%CI]), while food intake increased in HighEBMIL (+23% [2,44])., Conclusions: Primary WL failure after RYGB was not characterized by impaired secretions of appetite regulating gut hormones. Interestingly, inhibition of gut hormone secretions with octreotide only increased food intake in patients with successful WL post-RYGB. Thus, an impaired central anorectic response to gut hormones may contribute to primary WL failure after RYGB., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
127. Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapy.
- Author
-
Kjeldsen SAS, Gluud LL, Werge MP, Pedersen JS, Bendtsen F, Alexiadou K, Tan T, Torekov SS, Iepsen EW, Jensen NJ, Richter MM, Goetze JP, Rungby J, Hartmann B, Holst JJ, Holst B, Holt J, Gustafsson F, Madsbad S, Svane MS, Bojsen-Møller KN, and Wewer Albrechtsen NJ
- Abstract
Inhibitors of neprilysin improve glycemia in patients with heart failure and type 2 diabetes (T2D). The effect of weight loss by diet, surgery, or pharmacotherapy on neprilysin activity (NEPa) is unknown. We investigated circulating NEPa and neprilysin protein concentrations in obesity, T2D, metabolic dysfunction-associated steatotic liver disease (MASLD), and following bariatric surgery, or GLP-1-receptor-agonist therapy. NEPa, but not neprilysin protein, was enhanced in obesity, T2D, and MASLD. Notably, MASLD associated with NEPa independently of BMI and HbA1c. NEPa decreased after bariatric surgery with a concurrent increase in OGTT-stimulated GLP-1. Diet-induced weight loss did not affect NEPa, but individuals randomized to 52-week weight maintenance with liraglutide (1.2 mg/day) decreased NEPa, consistent with another study following 6-week liraglutide (3 mg/day). A 90-min GLP-1 infusion did not alter NEPa. Thus, MASLD may drive exaggerated NEPa, and lowered NEPa following bariatric surgery or liraglutide therapy may contribute to the reported improved cardiometabolic effects., Competing Interests: The authors declare no competing interests., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
128. Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight.
- Author
-
Svane MS, Johannesen HH, Hansen AE, Martinussen C, Bojsen-Møller KN, Hansen ML, Deacon CF, Keller SH, Klausen TL, Loft A, Kjaer A, Löfgren J, Madsbad S, Holst JJ, and Wewer Albrechtsen NJ
- Subjects
- Humans, Male, Adult, Middle Aged, Glucagon-Like Peptide-1 Receptor agonists, Glucagon, Overweight drug therapy, Overweight metabolism, Hypoglycemic Agents pharmacology, Hypoglycemic Agents therapeutic use, Insulin therapeutic use, Liver metabolism, Alanine therapeutic use, Amino Acids, Liraglutide pharmacology, Liraglutide therapeutic use, Diabetes Mellitus, Type 2 metabolism
- Abstract
We investigated the effect of pharmacologically induced weight loss on markers of glucagon resistance in individuals with overweight during treatment with the glucagon-like peptide-1 receptor agonist liraglutide. We performed an open-label study in 14 men with overweight (age 38 ± 11 years, BMI 32 ± 4 kg/m
2 ) without simultaneously diabetes. Subjects were treated with liraglutide, initiated and titrated with 0.6 mg/day/week to reach the final dose of 3.0 mg/day. Subjects were examined at baseline, during titration (Week 4), after 2 weeks of steady state (Week 6) of final dosing of liraglutide and 3 weeks after discontinuation of liraglutide (follow-up). Study participants lost 3.3 ± 1.9 kg (3%) total body weight during the first 4 weeks of treatment with liraglutide. Simultaneously, liver fat content decreased from 12.4 ± 11.6% to 10.2 ± 11.1%, p = 0.025, whereas fat content in the spleen and subcutaneous tissue was unaltered. Markers of glucagon resistance, including plasma glucagon and the glucagon-alanine-index, also decreased significantly during treatment, but total and individual plasma amino acid concentrations did not. Insulin resistance (HOMA-IR) was unchanged during treatment, whereas insulin clearance increased. Treatment with the GLP-1 receptor analogue liraglutide decreased liver fat content, and simultaneously attenuated glucagon concentrations and the glucagon-alanine index in individuals with overweight without diabetes., (© 2022. The Author(s), under exclusive licence to Springer Nature Limited.)- Published
- 2022
- Full Text
- View/download PDF
129. Neurotensin secretion after Roux-en-Y gastric bypass, sleeve gastrectomy, and truncal vagotomy with pyloroplasty.
- Author
-
Svane MS, Øhrstrøm CC, Plamboeck A, Jørgensen NB, Bojsen-Møller KN, Dirksen C, Martinussen C, Vilsbøll T, Hartmann B, Deacon CF, Kristiansen VB, Knop FK, Svendsen LB, Madsbad S, Holst JJ, and Veedfald S
- Subjects
- Blood Glucose, Glucagon-Like Peptide 1 blood, Humans, Hypoglycemic Agents pharmacology, Hypoglycemic Agents therapeutic use, Liraglutide administration & dosage, Liraglutide therapeutic use, Obesity blood, Obesity drug therapy, Postprandial Period, Gastrectomy, Gastric Bypass, Neurotensin blood, Obesity surgery, Vagotomy, Truncal
- Abstract
Objective: Neurotensin (NT) is released from enteroendocrine cells and lowers food intake in rodents. We evaluated postprandial NT secretion in humans after surgeries associated with accelerated small intestinal nutrient delivery, and after Roux-en-Y gastric bypass (RYGB) when glucagon-like peptide-1 (GLP-1) signalling and dipeptidyl peptidase 4 (DPP-4) were inhibited, and during pharmacological treatments influencing entero-pancreatic functions., Methods: We measured NT concentrations in plasma from meal studies: (I) after truncal vagotomy with pyloroplasty (TVP), cardia resection +TVP (CTVP), and matched controls (n = 10); (II) after RYGB, sleeve gastrectomy (SG), and in matched controls (n = 12); (III) after RYGB (n = 11) with antagonism of GLP-1 signalling using exendin(9-39) and DPP-4 inhibition using sitagliptin; (IV) after RYGB (n = 11) during a run-in period and subsequent treatment with, sitagliptin, liraglutide (GLP-1 receptor agonist), verapamil (calcium antagonist), acarbose (alpha glucosidase inhibitor), and pasireotide (somatostatin analogue), respectively., Results: (I) NT secretion was similar after TVP/CTVP (p = 0.9), but increased vs. controls (p < 0.0001). (II) NT secretion was increased after RYGB vs. SG and controls (p < 0.0001). NT responses were similar in SG and controls (p = 0.3), but early postprandial NT concentrations were higher after SG (p < 0.05). (III) Exendin (9-39) and sitagliptin did not change NT responses vs placebo (p > 0.2), but responses were lower during sitagliptin vs. exendin(9-39) (p = 0.03). (IV) Pasireotide suppressed NT secretion (p = 0.004). Sitagliptin tended to lower NT secretion (p = 0.08). Liraglutide, verapamil, and acarbose had no effect (p > 0.9)., Conclusion: Neurotensin secretion is increased after surgeries associated with accelerated gastric emptying and lowered by pasireotide., (© 2021 John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
130. Plasma GDF15 levels are similar between subjects after bariatric surgery and matched controls and are unaffected by meals.
- Author
-
Martinussen C, Svane MS, Bojsen-Møller KN, Jensen CZ, Kristiansen VB, Bookout AL, Jørgensen SB, Holst JJ, Wewer Albrechtsen NJ, Madsbad S, and Kuhre RE
- Subjects
- Adult, Blood Glucose analysis, Body Mass Index, Case-Control Studies, Cross-Over Studies, Female, Follow-Up Studies, Humans, Insulin blood, Male, Middle Aged, Obesity, Morbid pathology, Obesity, Morbid surgery, Postprandial Period, Prognosis, Randomized Controlled Trials as Topic, Weight Loss, Bariatric Surgery methods, Biomarkers blood, Gastrointestinal Tract metabolism, Growth Differentiation Factor 15 blood, Meals, Obesity, Morbid blood
- Abstract
Growth differentiating factor 15 (GDF15) is expressed in the intestine and is one of the most recently identified satiety peptides. The mechanisms controlling its secretion are unclear. The present study investigated whether plasma GDF15 concentrations are meal-related and if potential responses depend on macronutrient type or are affected by previous bariatric surgery. The study included 1 ) volunteers ingesting rapidly vs. slowly digested carbohydrates (sucrose vs. isomaltose; n = 10), 2 ) volunteers who had undergone Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) surgery and unoperated matched controls ingesting a liquid mixed meal ( n = 9-10 in each group), and 3 ) individuals with previous RYGB compared with unoperated controls ingesting isocaloric glucose, fat, or protein ( n = 6 in each group). Plasma was collected after an overnight fast and up to 6 h after ingestion (≥12 time points). In cohort 1 , fasting GDF15 concentrations were ∼480 pg/mL. Concentrations after sucrose or isomaltose intake did not differ from baseline ( P = 0.26 to P > 0.99) and total area under the curves (tAUCs were similar between groups ( P = 0.77). In cohort 2 , fasting GDF15 concentrations were as follows (pg/mL): RYGB = 540 ± 41.4, SG = 477 ± 36.4, and controls = 590 ± 41.8, with no between-group differences ( P = 0.73). Concentrations did not increase at any postprandial time point (over all time factor: P = 0.10) and tAUCs were similar between groups ( P = 0.73). In cohort 3 , fasting plasma GDF15 was similar among the groups ( P > 0.99) and neither glucose, fat, nor protein intake consistently increased the concentrations. In conclusion, we find that plasma GDF15 was not stimulated by meal intake and that fasting concentrations did not differ between RYGB-, SG-, and body mass index (BMI)-matched controls when investigated during the weight stable phase after RYGB and SG. NEW & NOTEWORTHY Our combined data show that GDF15 does not increase in response to a liquid meal. Moreover, we show for the first time that ingestion of sucrose, isomaltose, glucose, fat, or protein also does not increase plasma GDF15 concentrations, questioning the role of GDF15 in regulation of food source preference. Finally, we find that neither fasting nor postprandial plasma GDF15 concentrations are increased in individuals with previous bariatric surgery compared with unoperated body mass index (BMI)-matched controls.
- Published
- 2021
- Full Text
- View/download PDF
131. The role of GLP-1 in postprandial glucose metabolism after bariatric surgery: a narrative review of human GLP-1 receptor antagonist studies.
- Author
-
Hindsø M, Svane MS, Hedbäck N, Holst JJ, Madsbad S, and Bojsen-Møller KN
- Subjects
- Blood Glucose, Gastrectomy, Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor, Humans, Insulin, Bariatric Surgery, Diabetes Mellitus, Type 2, Gastric Bypass
- Abstract
The Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) bariatric procedures lead to remission or improvement of type 2 diabetes. A weight loss-independent augmentation of postprandial insulin secretion contributes to the improvement in glycemic control after RYGB and is associated with a ∼10-fold increase in plasma concentrations of the incretin hormone glucagon-like peptide-1 (GLP-1). However, the physiologic importance of the markedly increased postprandial GLP-1 secretion after RYGB has been much debated. The effect of GLP-1 receptor blockade after RYGB has been investigated in 12 studies. The studies indicate a shift toward a more prominent role for GLP-1 in postprandial β-cell function after RYGB. The effect of GLP-1 receptor antagonism on glucose tolerance after RYGB is more complex and is associated with important methodological challenges. The postprandial GLP-1 response is less enhanced after SG compared with RYGB. However, the effect of GLP-1 receptor blockade after SG has been examined in 1 study only and needs further investigation., (Copyright © 2021 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
132. Follistatin secretion is enhanced by protein, but not glucose or fat ingestion, in obese persons independently of previous gastric bypass surgery.
- Author
-
Bojsen-Møller KN, Svane MS, Jensen CZ, Kjeldsen SAS, Holst JJ, Wewer Albrechtsen NJ, and Madsbad S
- Subjects
- Activins blood, Adult, Female, Humans, Male, Middle Aged, Obesity blood, Postprandial Period, Dietary Fats, Dietary Proteins, Follistatin blood, Gastric Bypass, Glucose, Obesity surgery
- Abstract
Follistatin is secreted from the liver and is involved in the regulation of muscle mass and insulin sensitivity via inhibition of activin A in humans. The secretion of follistatin seems to be stimulated by glucagon and inhibited by insulin, but only limited knowledge on the postprandial regulation of follistatin exists. Moreover, results on postoperative changes after Roux-en-Y gastric bypass (RYGB) are conflicting with reports of increased, unaltered, and lowered fasting concentrations of follistatin. In this study, we investigated postprandial follistatin and activin A concentrations after intake of isocaloric amounts of protein, fat, or glucose in subjects with obesity with and without previous RYGB to explore the regulation of follistatin by the individual macronutrients. Protein intake enhanced follistatin concentrations similarly in the two groups, whereas glucose and fat ingestion did not change postprandial follistatin concentrations. Concentrations of activin A were lower after protein intake compared with glucose intake in RYGB. Glucagon concentrations were also particularly enhanced by protein intake and tended to correlate with follistatin in RYGB. In conclusion, we demonstrated that protein intake, but not glucose or fat, is a strong stimulus for follistatin secretion in subjects with obesity and that this regulation is maintained after RYGB surgery. NEW & NOTEWORTHY Circulating follistatin and activin A were studied after intake of isocaloric protein, fat, or glucose drinks in subjects with obesity with and without previous Roux-en-Y gastric bypass (RYGB). Protein intake enhanced follistatin similarly in both groups, whereas glucose and fat ingestion did not change follistatin. Activin A was lower after protein compared with glucose in RYGB. The novel finding is that protein intake, but neither glucose nor fat, stimulates follistatin secretion independently of previous RYGB.
- Published
- 2021
- Full Text
- View/download PDF
133. Successful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Sulfonylurea in the Treatment of KCNJ11 Neonatal Diabetes.
- Author
-
Hindsø M, Martinussen C, Svane MS, Veedfald S, Gade-Rasmussen B, Hansen T, and Madsbad S
- Abstract
Sulfonylurea monotherapy is the standard treatment for patients with the most common form of permanent neonatal diabetes, KCNJ11 neonatal diabetes, but it is not always sufficient. For the first time, we present a case of successful use of a GLP-1 receptor agonist as add-on therapy in the treatment of a patient with KCNJ11 neonatal diabetes and insufficient effect of sulfonylurea monotherapy. Good glycaemic control was maintained with a HbA1c level of 48 mmol/mol (6.5%) at the end of 26 months' follow-up., Learning Points: Genetic testing is important in patients with neonatal diabetes.Sulfonylurea is the standard treatment for patients with the most common mutation ( KCNJ11 ).We present the novel use of a GLP-1 receptor agonist as effective add-on therapy in a patient with KCNJ11 neonatal diabetes and insufficient effect of sulfonylurea monotherapy., Competing Interests: Conflicts of Interests: The authors did not receive funding for this work. MSS has received funding from the Danish Diabetes Academy for research not related to this work. SM has received research funding from Novo Nordisk and Boehringer-Ingelheim and honoraria from AstraZeneca, MSD, Sanofi and Novo Nordisk for research activities not related to this work., (© EFIM 2021.)
- Published
- 2021
- Full Text
- View/download PDF
134. [Multidisciplinary treatment of acute iron poisoning due to suicide attempt].
- Author
-
Petersen SM, Boysen T, Svane MS, and Christensen MB
- Subjects
- Antidotes therapeutic use, Female, Humans, Iron, Suicide, Attempted, Therapeutic Irrigation, Drug Overdose therapy, Poisoning
- Abstract
Intentional iron overdoses have an insidious and potentially fatal clinical course. This is a case report of a young woman, who deliberately ingested 300 tablets ferrous fumarate 330 mg, i.e. 400 mg elementary iron per kg body weight. Plain abdominal radiographs showed a conglomerate of iron tablets in the ventricle. Treatment consisted of endoscopic removal of tablets, deferoxamine antidote treatment, and whole bowel irrigation with macrogol laxatives. Toxicological risk evaluation of intentional iron overdoses is necessary to timely effectuate life-saving multidisciplinary empiric treatments.
- Published
- 2020
135. Bilio-enteric flow and plasma concentrations of bile acids after gastric bypass and sleeve gastrectomy.
- Author
-
Eiken A, Fuglsang S, Eiken M, Svane MS, Kuhre RE, Wewer Albrechtsen NJ, Hansen SH, Trammell SAJ, Svenningsen JS, Rehfeld JF, Bojsen-Møller KN, Jørgensen NB, Holst JJ, Madsbad S, Madsen JL, and Dirksen C
- Subjects
- Adult, Bile Ducts metabolism, Female, Fibroblast Growth Factors blood, Humans, Male, Middle Aged, Obesity, Morbid surgery, Postprandial Period physiology, Bile Acids and Salts blood, Bile Acids and Salts metabolism, Gastrectomy statistics & numerical data, Gastric Bypass statistics & numerical data
- Abstract
Background/objectives: Bile acids in plasma are elevated after bariatric surgery and may contribute to metabolic improvements, but underlying changes in bile flow are poorly understood. We assessed bilio-enteric flow of bile and plasma bile concentrations in individuals with Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) surgery compared with matched non-surgical controls (CON)., Subjects/methods: Fifteen RYGB, 10 SG and 15 CON underwent
99 Tc-mebrofenin cholescintigraphy combined with intake of a high-fat111 In-DTPA-labelled meal and frequent blood sampling. A75 Se-HCAT test was used to assess bile acid retention., Results: After RYGB, gallbladder filling was decreased (p = 0.045 versus CON), basal flow of bile into the small intestine increased (p = 0.005), bile acid retention augmented (p = 0.021) and basal bile acid plasma concentrations elevated (p = 0.009). During the meal, foods passed unimpeded through the gastric pouch resulting in almost instant postprandial mixing of bile and foods, but the postprandial rise in plasma bile acids was brief and associated with decreased overall release of fibroblast growth factor-19 (FGF-19) compared with CON (p = 0.033). After SG, bile flow and retention were largely unaltered (p > 0.05 versus CON), but gastric emptying was accelerated (p < 0.001) causing earlier mixture of bile and foods also in this group. Neither basal nor postprandial bile acid concentrations differed between SG and CON., Conclusions: Bilio-enteric bile flow is markedly altered after RYGB resulting in changes in plasma concentrations of bile acids and FGF-19, whereas bile flow and plasma concentrations are largely unaltered after SG.- Published
- 2020
- Full Text
- View/download PDF
136. [Successful treatment of KCNJ11 neonatal diabetes without insulin].
- Author
-
Gade-Rasmussen B, Madsbad S, Svane MS, Martinussen C, and Hansen T
- Subjects
- Adult, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Liraglutide, Male, Sulfonylurea Compounds, Diabetes Mellitus drug therapy, Diabetes Mellitus genetics, Diabetes Mellitus, Type 2, Potassium Channels, Inwardly Rectifying genetics
- Abstract
In this case report a 40-year-old insulin-treated male patient presented with a KCNJ11 R201H mutation, which can cause neonatal diabetes. After initiation of treatment with high doses of the sulfonylurea glibencamide in combination with the glucagon-like peptide 1 receptor agonist liraglutide, insulin treatment of the patient could be terminated. The first nine months after termination of insulin treatment the glycated haemoglobin concentration was 48-54 mmol/mol (i.e. 6.5-7.1%).
- Published
- 2018
137. Emerging drugs for the treatment of obesity.
- Author
-
Martinussen C, Bojsen-Moller KN, Svane MS, Dejgaard TF, and Madsbad S
- Subjects
- Animals, Anti-Obesity Agents administration & dosage, Anti-Obesity Agents adverse effects, Appetite Depressants administration & dosage, Appetite Depressants adverse effects, Drug Design, Drug Therapy, Combination, Humans, Molecular Targeted Therapy, Time Factors, Weight Loss drug effects, Anti-Obesity Agents therapeutic use, Appetite Depressants therapeutic use, Obesity drug therapy
- Abstract
Introduction: The increasing prevalence of obesity represents a huge threat to public health and the current pharmacological treatment options are limited. Bariatric surgery is by far the most effective treatment for severe obesity, highlighting the urgent need for new and improved drug therapies. Areas covered: Based on the physiological regulation of energy homeostasis, pharmacological strategies to treat obesity are evaluated with focus on drugs in phase 2 and 3 clinical development. The potential impact of these drugs on current treatment standards and the barriers for development are discussed and set in a historical perspective of previous antiobesity medications. Expert opinion: The radical effects of bariatric surgery have extended our understanding of the mechanisms controlling appetite and boosted the search for new drug targets in obesity treatment. Accordingly, several compounds targeting the central nervous system and/or periphery are in pipeline for obesity. These drugs should be evaluated over a wide array of end-points; in particular, long-term safety monitoring is necessary as serious adverse events may appear. Combination therapy targeting more than one pathway controlling energy balance might be necessary to achieve substantial weight loss while minimising side effects.
- Published
- 2017
- Full Text
- View/download PDF
138. [Medical therapy versus bariatric surgery of obese patients with Type 2 diabetes].
- Author
-
Svane MS, Bojsen-Møller KN, and Madsbad S
- Subjects
- Bariatric Surgery, Blood Glucose analysis, Diabetes Complications prevention & control, Glycated Hemoglobin analysis, Humans, Life Style, Recurrence, Remission Induction, Weight Loss, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 surgery, Obesity complications, Obesity drug therapy, Obesity surgery
- Abstract
Bariatric surgery induces large and sustainable weight loss in obese patients and improves glycaemic control in patients with Type 2 diabetes. Eleven randomized controlled trials have shown superior glycaemic outcomes after bariatric procedures vs. medical therapy/intensive lifestyle interventions in obese patients with Type 2 diabetes. Furthermore, many patients experience remission of Type 2 diabetes after surgery but relapse may occur during follow-up. Data from observational studies show reduced incidence of micro- and macrovascular complications in addition to reduced cardiovascular and total mortality after surgery.
- Published
- 2016
139. Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery.
- Author
-
Svane MS, Bojsen-Møller KN, Nielsen S, Jørgensen NB, Dirksen C, Bendtsen F, Kristiansen VB, Hartmann B, Holst JJ, and Madsbad S
- Subjects
- Adult, Blood Glucose drug effects, Cross-Over Studies, Enzyme-Linked Immunosorbent Assay, Female, Glucagon drug effects, Glucagon-Like Peptide-1 Receptor antagonists & inhibitors, Glucose Tolerance Test methods, Humans, Hypoglycemic Agents pharmacology, Linear Models, Male, Obesity metabolism, Peptide Fragments pharmacology, Postprandial Period, Single-Blind Method, Sitagliptin Phosphate pharmacology, Blood Glucose metabolism, C-Peptide metabolism, Gastric Bypass, Gastric Inhibitory Polypeptide metabolism, Glucagon metabolism, Glucagon-Like Peptide 1 metabolism, Obesity surgery
- Abstract
Exaggerated secretion of glucagon-like peptide 1 (GLP-1) is important for postprandial glucose tolerance after Roux-en-Y gastric bypass (RYGB), whereas the role of glucose-dependent insulinotropic polypeptide (GIP) remains to be resolved. We aimed to explore the relative importance of endogenously secreted GLP-1 and GIP on glucose tolerance and β-cell function after RYGB. We used DPP-4 inhibition to enhance concentrations of intact GIP and GLP-1 and the GLP-1 receptor antagonist exendin-(9-39) (Ex-9) for specific blockage of GLP-1 actions. Twelve glucose-tolerant patients were studied after RYGB in a randomized, placebo-controlled, 4-day crossover study with standard mixed-meal tests and concurrent administration of placebo, oral sitagliptin, Ex-9 infusion, or combined Ex-9-sitagliptin. GLP-1 receptor antagonism increased glucose excursions, clearly attenuated β-cell function, and aggravated postprandial hyperglucagonemia compared with placebo, whereas sitagliptin had no effect despite two- to threefold increased concentrations of intact GLP-1 and GIP. Similarly, sitagliptin did not affect glucose tolerance or β-cell function during GLP-1R blockage. This study confirms the importance of GLP-1 for glucose tolerance after RYGB via increased insulin and attenuated glucagon secretion in the postprandial state, whereas amplification of the GIP signal (or other DPP-4-sensitive glucose-lowering mechanisms) did not appear to contribute to the improved glucose tolerance seen after RYGB., (Copyright © 2016 the American Physiological Society.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.